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ABSTRAK 
 
Pseudomonas aeruginosa adalah sejenis bakteria pathogen yang secara 
intrinsiknya rintang terhadap pelbagai jenis antibiotik. Faktor utama yang menyumbang 
ke arah kerintangan intrinsik ini adalah disebabkan oleh lapisan membran yang kurang 
telap dan pengekspresian pelbagai pam efluks. Salah satu strategi yang menarik untuk 
mengatasi masalah kerintangan dalam bakteria adalah dengan penggunaan perencat pam 
efluks (EPI). Dalam kajian ini, potensi asid kafeik dan terbitannya untuk bertindak 
sebagai EPI diramal dengan menggunakan kaedah in siliko pendokan molekul dan 
dinilai secara in vitro menggunakan asai pengumpulan etidium bromida (EtBr). Dua 
protein yang memainkan peranan utama dalam pengangkutan keluar antibiotik dalam P. 
aeruginosa (MexB dan MexY) telah digunakan sebagai protein sasaran. Berdasarkan 
kajian interaksi protein-ligand, ester feniletil asid kafeik (CAPE) dan amida feniletil asid 
kafeik (CAPA) yang memperolehi tenaga bebas pengikatan yang terendah dalam kedua- 
dua protein telah dikenalpasti berpotensi sebagai calon EPI. Potensi asid kaffeik, CAPE 
dan CAPA untuk bertindak sebagai EPI dalam P. aeruginosa telah dinilai melalui asai 
pengumpulan EtBr. Antara tiga sebatian yang diuji, CAPE didapati sangat berkesan 
dalam menyebabkan peningkatan pengumpulan EtBr intraselular dalam P. aeruginosa. 
Untuk tempoh jangka waktu 5 minit, peningkatan sebanyak 21.4% dalam pendafluor 
telah diperhatikan dalam P. aeruginosa. Ini menyarankan bahawa CAPE berupaya 
mengganggu gugat sistem pam efflux, dan membawa kepada pengumpulan EtBr dalam 
xvii  
sel bakteria ini. Kombinasi setiap satu sebatian yang diuji (CAPE, CAPA dan asid 
kafeik) dengan suatu sebatian aminoglikosida, kanamisin juga telah menyebabkan 
penurunan kepekatan merencat minima (MIC) pada faktor 4-kali ganda sehingga 8-kali 
ganda. Dengan itu, berdasarkan interaksi ikatan yang baik ditunjukkan oleh CAPE 
melalui kaedah in siliko pendokan molekul dan keupayaannya untuk mengumpulkan 
lebih banyak EtBr dalam P. aeruginosa daripada asid kafeik dan CAPA melalui asai 
pengumpulan EtBr, hasil kajian ini mencadangkan CAPE berpotensi sebagai perencat 
pam efluks dalam P. aeruginosa. Keupayaan CAPE dan terbitan asid kafeik lain yang 
dikaji untuk mengurangkan MIC kanamisin dalam P. aeruginosa juga turut 
meningkatkan potensi terbitan asid kafeik ini sebagai EPI, justeru dapat memperbaiki 
keberkesanan aminoglikosida ini sebagai ajen antimikrob. 
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In Silico PREDICTION AND In Vitro EVALUATION OF CAFFEIC ACID AND 
ITS DERIVATIVES AS POTENTIAL EFFLUX PUMP 
INHIBITOR(S) IN Pseudomonas aeruginosa 
 
 
ABSTRACT 
 
Pseudomonas aeruginosa is a bacterial pathogen that is intrinsically resistant 
towards various antibiotics. The main factors that contribute to this intrinsic resistance 
are due to the lower outer membrane permeability and expression of multiple efflux 
pumps. One of the promising strategies to circumvent the problem of bacterial resistance 
is the use of efflux pump inhibitor (EPI). In this study, the efflux pump inhibitory 
potential of caffeic acid and its derivatives were predicted using in silico molecular 
docking, and accessed using in vitro ethidium bromide (EtBr) accumulation assay. Two 
proteins (MexB and MexY) that play important roles in the effluxing of antibiotics in P. 
aeruginosa were used as the target proteins. Based on the protein-ligand interaction 
studies, caffeic acid phenethyl ester (CAPE) and caffeic acid phenethyl amide (CAPA) 
that scored the lowest free energy of binding in both proteins were identified as potential 
EPI candidates. The potential of caffeic acid, CAPE and CAPA to act as EPIs in P. 
aeruginosa was evaluated using ethidium bromide (EtBr) accumulation assay. Among 
the three compounds tested, CAPE was found to significantly increase the intracellular 
accumulation of EtBr in P. aeruginosa. An increase of 21.4% in fluorescence over 5- 
min time frame was observed in P. aeruginosa. This suggests that CAPE was able to 
disrupt or compromise the efflux pumps, thus leading to the accumulation of EtBr in 
these bacterial cells. Combination of each test compound (CAPE, CAPA and caffeic 
acid) with an aminoglycoside, kanamycin has reduced the minimum inhibitory 
xix  
concentration (MIC) by 4-folds to 8-folds. Thus, based on the good binding interaction 
showed by CAPE from the in silico molecular docking study and its ability to 
accumulate higher EtBr in P. aeruginosa than caffeic acid and CAPA in the in vitro  
EtBr accumulation assay, these suggest that CAPE has the potential to act as an EPI in 
P. aeruginosa. The ability of CAPE and the other caffeic acid derivatives tested to 
reduce the MIC of kanamycin in P. aeruginosa further promote the potency of of these 
caffeic acid derivatives as EPIs, thus improving the efficacy of this aminoglycoside as 
an antimicrobial agent. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background of study and problem statement 
 
 
The alarming rate of antimicrobial resistance and continuous emergence of 
multidrug resistant (MDR) bacteria pathogens in various environments have made the 
control and management of infectious diseases a daunting task. Recently, the World 
Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) 
highlighted this issue as a serious threat to public health that requires action from the 
government sector and society all around the world (CDC, 2016; WHO, 2018). This is 
due to the fact that the patients who are infected by MDR pathogens are prone to 
experience increased risk of adverse clinical outcomes than the patients infected with 
non-resistant bacteria (WHO, 2018). Consequently, the patients will consume more 
healthcare resources and require higher dose of antimicrobial agents that can be harmful. 
 
Apart from the extensive use of antimicrobial agents in various clinical settings, 
the existence of various efflux mechanisms in most of the MDR pathogens has been 
broadly recognized as the major resistance component (Poole, 2001; Piddock, 2006; 
Anes et al., 2015). The mechanisms of drug efflux in bacteria are intricate, where some 
can be resistant for specific antibiotics while others, such as MDR efflux pumps, can 
confer resistance to variety of structurally and functionally unrelated compounds. These 
compounds include ethidium bromide (EtBr), acriflavine, triclosan, organic solvents and 
acylated homoserine lactones (Piddock, 2006). Examples of major antibiotic classes that 
are  known  to  be  effluxed  by  the  intrinsic  bacterial  efflux  pumps  systems  include 
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macrolides, β-lactams, fluoroquinolones, oxazolidinones, fourth-generation 
cephalosporins and carbapenems (Kumar and Schweizer, 2005). 
 
Pseudomonas aeruginosa is an opportunistic human pathogen, recognized as 
ubiquitous organism due to its ability to survive and adapt in a wide range of 
environment (Matthew et al., 2003). P. aeruginosa is also one of the leading causes of 
nosocomial infections (Weinstein et al., 2005). Immuno-compromised individuals with 
underlying diseases such as cystic fibrosis, cancer and diabetes, and in patients who 
suffered burns or other severe trauma are particularly susceptible to P. aeruginosa 
infections (Botzenhart and Döring, 1993; Kominos et al., 1972). For example, in the 
United States of America, the threat level by MDR P. aeruginosa has been characterized 
as very serious, with 6700 MDR Pseudomonas infection and 440 death in 2014 (CDC, 
2014). 
 
Over the years, P. aeruginosa has become increasingly resistant towards many 
antimicrobials, leading them to be known as a ‘superbug’ (Breidenstein et al., 2011). 
The intrinsic resistance in P. aeruginosa towards multiple classes of antibiotics is most 
probably contributed by the expression of MDR efflux pumps of the resistance- 
nodulation-cell-division (RND) superfamily (Li et al., 1994; Lynch et al.,, 1997; 
Piddock, 2006; Strateva and Yordanov, 2009). These efflux pumps include the 
constitutively expressed MexAB-OprM and MexXY-OprM, and the inducible MexCD- 
OprF and MexEF-OprN operons (Kumar and Schweizer, 2005; Piddock, 2006). The 
ability of these efflux pumps to facilitate the extrusion of antibiotics has limited their 
accumulation inside the cell; thus making the antibiotics less effective. 
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The usage of efflux pump inhibitor(s) (EPI) offers a very promising approach to 
minimize the effluxing of drugs. EPI is a small molecule that acts as an adjuvant to 
enhance the activity of conventional and/or older-generation antibiotics. This molecule 
usually binds to the efflux pump either competitively or non-competitively and thwarts 
the extrusion of antibiotics. In addition, the application of EPI in the treatment of 
bacterial infections can also elevate drug potency and reduce the development of new 
bacterial resistant strain (Zechini and Versace, 2009). To date, many EPIs have been 
discovered, including the established EPI, phenyl-arginine beta-naphthylamide (PAβN). 
PAβN was the first broad-spectrum RND pump inhibitor that could inhibit all the four 
clinically significant efflux systems in P. aeruginosa and as well as other Gram- 
Negative bacteria (Lomovskaya et al., 2001; Mamelli et al., 2003; Hasdemir et al., 
2004). However, to date, this EPI has not reached the clinical usage, probably due to its 
unfavourable pharmacokinetics and toxicological profiles (Lomovskaya and Bostian, 
2006) and its effect on the membrane integrity of bacteria (Lomovskaya et al., 2001; 
Lamers et al. 2013). 
 
For centuries, plants have been widely used as traditional medicine for the 
treatment of diseases related to bacterial, fungal and viral infections (Dupont et al., 
2006; Temrangsee et al., 2011). The abundance of phytochemicals with diverse 
functional groups and chirality in plants also contributes towards many health-promoting 
benefits. Hence, taking advantage of the therapeutic potential of plant resources as 
antimicrobials, this research is conducted to evaluate the use of caffeic acid and its 
derivatives as potential EPI(s) for P. aeruginosa. Caffeic acid is a phytochemical 
ubiquitiously found in plants and herbs. Caffeic acid and its derivatives, such as 
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chlorogenic acid and caffeic acid phenethyl ester (CAPE) have been shown to 
demonstrate various pharmaceutical properties such as antibacterial, anticancer, 
antifungal, antioxidant and antiviral (Mirzoeva et al., 1993; Chen et al., 1996; Tsuchiya 
et al., 1996; Tamura et al., 2006; Fatoni et al., 2008; Lou et al., 2011). Therefore, by 
assessing the efflux pump inhibitory activities of the caffeic acid and its derivatives, it 
could give an insight as to how effective these phytochemicals could reduce the MDR 
problem in P. aeruginosa, thus enhancing the antimicrobial efficacy. 
 
1.2 Objectives of study 
 
 
The general objective of this study is to identify and evaluate new candidate(s) of 
EPI from caffeic acid and its derivatives as an approach to reduce MDR-related problem 
in P. aeruginosa using in silico and in vitro approaches. The specific objectives of this 
study include: 
 
1. To predict the binding interaction of caffeic acid and its selected derivatives with 
the multidrug resistance efflux pumps MexB and MexY proteins in P. aeruginosa, using 
in silico molecular docking technique. 
 
2. To synthesize and characterize potential caffeic acid derivative candidate(s) 
based on the molecular docking results. 
 
3. To evaluate the efflux pump inhibitory activities of the selected caffeic acid 
derivatives from their ability to accumulate ethidium bromide (EtBr) and ability to 
reduce the minimum inhibitory concentration (MIC) of test antibiotics in P. aeruginosa, 
using in vitro assay. 
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CHAPTER 2: LITERATURE REVIEW 
 
 
2.1 Multidrug resistance of Pseudomonas aeruginosa 
 
 
Pseudomonas aeruginosa is a Gram-Negative rod bacterium that belongs to the 
family of Pseudomonadaceae. It is an opportunistic pathogen and has been recognized 
as the leading cause of life-threatening nosocomial infections in patients with impaired 
defenses (Weinstein et al., 2005). These include the patients suffering from burns and 
wounds, which can lead to bacteraemia during complication (Sadikot et al., 2005). In 
addition, it can also cause urinary tract infection, nosocomial pneumonia and chronic 
lung infections in cystic fibrosis (CF) patients (Hare et al., 2012). However, this 
bacterium rarely causes infection in healthy people. 
 
The infections caused by P. aeruginosa is due to its ability to survive in a wide 
range of environment such as in soil, water and plants (Matthew et al., 2003). In 
hospitals, this bacterium can spread through the cleaning solution, non-sterilized medical 
equipment or even via the hands of the healthcare workers (Kominos et al., 1972). 
Hence, this is why most hospitalized patients with weakened immune system are always 
at a higher risk of being infected by this organism (CDC, 2016). The risk of infection 
caused by P. aeruginosa in the Intensive Care Unit (ICU) also remains high with 
mortality rates as high as 30 % to 60 % in bacteraemia and up to 70 % in patients with 
nosocomial pneumonia (Aliaga et al., 2002; Alp et al., 2004). 
 
The treatment of infections caused by P. aeruginosa usually requires higher end 
antibiotics and higher healthcare cost (Carmeli et al., 1999; Slama, 2008). The common 
classes of antibiotics used to treat P. aeruginosa infections include aminoglycoside, 
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carbapenem, cephalosporin, penicillin, polymyxin and quinolone (Hancock and Speert, 
2000). The treatment of P. aeruginosa infection has become more challenging as the 
organism is becoming increasingly resistant towards these antibiotics. Thus, this 
bacterium has been categorized as multidrug resistant (MDR) organism due to its ability 
to resist more than one class of antibiotics (CDC, 2014). 
 
Among factors that can lead to the multidrug resistance in P. aeruginosa is due to 
the over reliance and inappropriate use of antibiotics (CDC, 2014). Besides this factor, 
P. aeruginosa is also associated with its high intrinsic resistance towards various 
antibiotics (Breidenstein et al., 2011). The low outer membrane permeability of P. 
aeruginosa has contributed to its high intrinsic resistance (Navon-Venezia et al., 2005; 
Hirsch and Tam, 2011). In addition, the ability of P. aeruginosa to survive in a wide 
range of environments also enables them to develop other intrinsic and adaptive 
secondary mechanisms of resistance such as the over-expression of multidrug efflux 
pumps (Li et al., 1995; Li et al., 2000) and β-lactamase production (Nakae et al., 1999). 
Table 2.1 summarizes the overview of the different types of resistance exhibited by P. 
aeruginosa. 
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Table 2.1: Overview of the different types of resistance exhibited by P. aeruginosa. 
 
Type of resistance Mechanisms Examples of genes 
involved 
Intrinsic Low outer  membrane 
permeability, β-lactamase 
production and efflux pump 
overexpression 
Acquired Horizontal transfer, mutations 
leading to reduced drug/substrate 
uptake and efflux pump 
overexpression 
Adaptive Gene expression changes 
including β-lactam and efflux 
pump overexpression due to the 
factors triggering expression of 
regulatory genes 
From Breidenstein et al.(2011). 
crc, lon, psrA 
 
 
 
ampD, gyrA, nalA, nfxB, 
cbrA, MBLs 
 
 
ampC, mexZ, phoQ 
 
 
Considering all the factors that lead to the antibiotic resistance, it is not  
surprising that P. aeruginosa has reached to the level of ‘superbug’ that is resistant to 
most of the currently available anti-pseudomonal antibiotics and actively developing 
MDR strain (Breidenstein et al., 2011). This problem is contributed by various 
mechanisms of resistance exhibited by P. aeruginosa. 
 
2.2 Mechanisms of bacterial antibiotic resistance 
 
 
Over the years, bacteria have evolved and developed sophisticated mechanisms 
of drug resistance in order to survive the effect of antibiotics. A single bacterium can 
exhibit various mechanisms of resistance at the same time, therefore, rendering them 
more difficult to be eradicated. Three fundamental mechanisms of antibiotic resistance 
in bacteria include the alteration of the bacterial target site; degradation or modification 
of the antibiotic and the reduction of the intracellular concentration of the antibiotic, by 
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decreased permeability of the cell wall or by the efflux of the antibiotic from the cell 
(Munita et al., 2016). Figure 2.1 describes the image for the different mechanisms of 
bacterial antibiotic resistance. 
 
 
Figure 2.1: Diagram of different mechanisms of bacterial antibiotic resistance. This 
picture was adapted from Encyclopedia-Britannica, (2009). 
 
2.2.1 Alteration of the bacterial target site 
 
In bacteria, alteration of the antibiotics target site can be achieved by: 
 
A. the target protection that prevent the antibiotics from reaching its target (e.g. the 
development of tetracycline resistance by the expression of tetracycline 
resistance determinants Tet(M) and Tet(O) in Steptococcus spp. and 
Campylobacter jejuni, respectively. These resistance determinants prevent the 
tetracycline from reaching their binding sites by interacting with the ribosome) 
(Connell et al., 2003), and/or by 
B. the modifications of the target site, which involve a few strategies, such as: 
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i. the point mutations in the genes encoding the target site (e.g. the evolution of 
rifampin (RIF) resistance via the inhibition of the DNA-dependent RNA 
polymerase binding site, encoded by rpoB gene that prevent bacterial 
transcription) (Campbell et al., 2001), 
ii. the enzymatic modifications of the binding site (e.g. the development of 
macrolide resistance through the methylation of the ribosome, which is catalyzed 
by an enzyme encoded erythromycin ribosomal methylation, erm genes) 
(Leclercq, 2002), and/or 
iii. the replacement or bypass of the original target (e.g. the development of 
methicillin resistance in Staphylococcus aureus caused by the acquisition of 
foreign gene, mecA that encodes penicillin-binding protein, PBP (PBP2a), which 
has low likeness towards all β-lactams) (Hiramatsu et al., 2013). 
2.2.2 Degradation or modification of the antibiotic 
 
Degradation or modification of antibiotics by the production of enzyme can be 
achieved by two main strategies: 
A. the chemical alterations of the antibiotic (e.g. the development of 
aminoglycosides resistance via the activity of aminoglycoside modifying 
enzymes (AMEs) that can covalently alter the amino or hydroxyl groups of the 
aminoglycoside molecule) (Ramirez and Tolmasky, 2010), and/or by 
B. the degradation of the antibiotic molecule (e.g. the evolution of β-lactam 
resistance by the production of β-lactamase enzyme that is able to destroy the 
amide bond of the β-lactam ring) (Abraham and Chain, 1940). 
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2.2.3 Decreased permeability of the cell wall or by efflux of antibiotics 
 
Two important mechanisms of resistance that prevent antibiotics from reaching 
its intracellular or periplasmic target include: 
A. the decrease uptake of the antibiotics due to the changes in the permeability of 
the outer membrane (e.g. resistance to β-lactams, tetracyclines and some 
fluoroquinolones) and/or due to the porin-mediated antibiotic resistance (e.g. the 
development of resistance to imipenem by the unusual production of OprD porin 
in P. aeruginosa) (Quinn et al., 1986), and/or by 
B. the efflux of antibiotics from within the cell or membrane by utilizing membrane 
bound protein transporter known as the efflux pump (e.g. resistance to various 
antibiotics due to the activity of the MexAB-OprM efflux pump in P. aeruginosa 
and AcrAB-TolC efflux pump in Escherichia coli (Piddock, 2006). 
Among the mechanisms of antibiotic resistance described, efflux appears be an 
important mechanism that contributes to the multidrug resistances in bacteria. Besides 
actively extruding antibiotics, efflux is also involved in the low intrinsic susceptibility, 
cross-resistance to chemically unrelated classes of molecules, and selection/acquisition 
of additional mechanisms of resistance (Mahamoud et al., 2007). 
2.3 Major classes of bacterial efflux pumps 
 
The genes encoding the efflux pumps can be either chromosomally or non- 
chromosomally (plasmid) encoded. They are often regulated at the level of transcription 
in response to the presence of high concentrations of drugs (Piddock, 2006). Two major 
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efflux pump transporters usually encoded in bacteria include primary transporter such as 
ATP-binding cassette (ABC) transporter, and secondary transporter, which includes 
major facilitator superfamily (MFS), small multidrug resistance (SMR), resistance- 
nodulation-cell division (RND), and multidrug and toxic compound extrusion (MATE). 
In general, primary transporter utilizes ATP hydrolysis as their energy source while 
secondary transporter derives energy from the trans-membrane proton or sodium ion 
gradient (Piddock, 2006). Figure 2.2 shows the five major super families of bacterial 
efflux pumps. 
 
 
Figure 2.2: Diagram of different major super families of bacterial efflux pump with 
their common substrates. This picture was adapted from (Piddock, 2006). 
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Of these transporters, RND pumps are primarily found in Gram-Negative 
bacteria. These pump not only play a major role in both their intrinsic and acquired 
resistance to a diverse clinically significant antibiotics, but can also efflux biocides, 
dyes, detergents and organic solvents (Kumar and Schweizer, 2005; Bhardwaj and 
Mohanty, 2012). Apart from that, there are also other type of efflux transporters present 
in Gram-Negative bacteria but are less prominent in mediating resistance to clinically 
relevant antibiotics (Nilsen et al., 1996; Edgar and Bibi, 1997; Miyamae et al., 1998). 
2.4 Resistance-nodulation-cell division efflux pumps encoded in P. aeruginosa 
 
The common efflux pumps that contribute to the multidrug resistance in P. 
aeruginosa mostly come from the RND super family (Kumar and Schweizer, 2005; 
Piddock, 2006). To date, 7 out of 12 RND pump-encoding operons have been 
characterized in this organism, which include: MexAB-OprM (Poole et al., 1993), 
MexXY-OprM (Mine et al., 1999), MexEF-OprN (Köhler et al., 1997), MexCD-OprJ 
(Poole et al., 1996), MexJK-OprM (Chuanchuen et al., 2002), MexGHI-OpmD 
(Aendekerk et al., 2002) and MexVW-OprM (Li et al., 2003). The major efflux systems 
responsible for the intrinsic and acquired resistance in this bacterium include MexAB- 
OprM, MexXY-OprM, MexEF-OprN and MexCD-OprJ (Kumar and Schweizer, 2005). 
The operons, MexAB-OprM and MexXY-OprM efflux systems, are constitutively 
expressed in P. aeruginosa, thus rendering this bacterium the ability to extrude multiple 
unrelated compounds (Bambeke et al., 2013). The list of substrates and regulators for 
each characterized RND efflux systems in this organism are summarized in Table 2.2. 
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Table 2.2: Resistance-nodulation-cell division-type multidrug efflux systems in P. 
aeruginosa 
 
Efflux componentsa Regulator (s) Substrates b References 
MFP RND OMP 
 
MexA MexB OprM MexR AC, AG, BL, CM, CV, 
EB, ML, NO, SDS, TC, 
TM, TR 
Poole et al., 
1993;  Li  et 
al., 1995; 
Poole et al., 
1996 
 
 
MexC MexD OprJ NfxB CM, CP, FQ, TC, TR Poole et al., 
1996 
 
MexE MexF OprN MexT CM, FQ  Köhler et 
al., 1997 
MexH MexI OpmD ? AC, EB, 
VD 
HL, NO, RD, Aendekerk 
et al., 2002; 
Sekiya et 
al., 2003 
 
 
MexJ MexK OprM/ 
OpmH 
MexL EM, TC, TR Chuanchue 
n et al., 
2002 
 
MexV MexW OprM ? AC, CM, EB, 
TC 
EM, FQ, Li et al., 
2003 
MexX MexY OprM MexZ AG, ML, TC   Mine et al., 
1999; 
Nikaido et 
al., 1999 
 
a
MFP: membrane fusion protein; RND: resistance-nodulation-cell-division; OMP: outer 
membrane protein. 
b
AC, acriflavine; AG, aminoglycosides; AP, ampicillin; BL, β-lactams, CM, 
chloramphenicol; CP, cephalosporins; CV, crystal violet; EB, ethidium bromide, EM, 
erythromycin; FQ, fluoroquinolones; HL, homoserine-lactones; ML, macrolides; NO, 
novobiocin; RD, rhodamine; SDS, sodium dodecyl sulfate; TC, tetracycline; TM, 
trimethoprim; TR, triclosan; VD, vanadium; ?, unknown. 
From Kumar and Schweizer, (2005), modified. 
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MexAB-OprM was the first RND efflux pump reported in P. aeruginosa and has 
the broadest substrate range of all characterized P. aeruginosa’s efflux pumps. Deletion 
of components of this efflux system in a wild-type strain of P. aeruginosa has made the 
strain hypersusceptible to many drugs such as chloramphenicol, fluoroquinolones, 
nalidixic acid and tetracycline (Poole et al., 1993; Li et al., 1995). Like MexAB-OprM, 
MexXY-OprM efflux system also contributes to the intrinsic resistance of P. aeruginosa 
towards several antibiotics including aminoglycosides, erythromycin and 
fluoroquinolones (Aires et al., 1999). 
2.4.1 Structure of MexAB-OprM and MexXY-OprM efflux pumps 
 
The main RND-type efflux pumps encoded in wild-type strain of P. aeruginosa 
(i.e. MexAB-OprM and MexXY-OprM) are comprised of a periplasmic membrane 
fusion protein (MFP) component, the inner-membrane drug/H+ antiporter or the RND 
component (IMP), and the outer-membrane channel (OMP) component. Figure 2.3 
shows the structure of the RND-type efflux pump based on the individual structures of 
MexAB-OprM efflux system in P. aeruginosa. 
Based on the tripartite RND efflux complex, the MFP (e.g. MexA or MexX) 
component has been identified to function as a membrane bridge protein that connects 
the IMP and the OMP components (Akama et al., 2004). This component is essential for 
the pump assembly and function, whereas the OMP (e.g. OprM) functions in facilitating 
the exit of the substrates out of the cell (Akama et al., 2004). Meanwhile, the inner 
membrane RND transporter, IMP (e.g. MexB or MexY) component plays the central 
role of the efflux pump that recognizes the molecule to be effluxed and catalyzes the pH 
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dependent drug transport (Sennhauser et al., 2009). This protein is involved in the 
extrusion of the substrates with the aid of the proton motive force (Venter et al., 2015). 
The tripartite assembly of this efflux system allows the direct extrusion of the substrates 
from the inner membrane to the extracellular medium (Bambeke et al., 2013). 
 
Figure 2.3: Schematic representation of a Resistance-Nodulation Division-type 
efflux pump. a) The pump consists of three proteins that span the inner membrane 
(CM), the periplasmic space and the outer membrane (OM). The proteins include the 
inner-membrane protein (IMP) that is connected to the outer-membrane protein (OMP) 
by the membrane fusion protein (MFP). The picture illustrated the process of drug (AB) 
extrusion by the efflux pump, which requires energy (H+). b) Protein structures of the 
individual components of the RND efflux pump; MFP (MexA; pdb: 2V4D), IMP 
(MexB; pdb: 2V50) and OMP (OprM; pdb: 1WP1) in P. aeruginosa. Picture was 
obtained from (Venter et al., 2015). 
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Both of the intrinsic RND pumps, MexB and MexY from MexAB-OprM and 
MexXY-OprM efflux systems, respectively, play major roles for the substrate specificity 
and energy of the transport process (Zgurskaya and Nikaido 1999; Elkins and Nikaido 
2002). These proteins are closely related to the AcrB pump in E. coli with sequence 
identity of 69.8% (MexB) and 51.0% (MexY), and sequence similarity of 83.2% 
(MexB) and 19.0% (MexY) (Sennhauser et al., 2009; Lau et al., 2014). The presence of 
these three-dimensional structures has given rise to a better understanding of the 
mechanism of efflux in Gram-Negative bacteria (Pagès et al., 2005). 
2.4.2 Mechanism of RND efflux pump in Gram-Negative bacteria 
 
The presence of crystal structures from the RND efflux pump and 
antibiotic/inhibitor-bound RND efflux pump has shed light towards a better 
understanding of the mechanism of drug efflux. For instance, Murakami et al. in 2006 
had revealed the functionally rotating mechanism of the RND efflux pump using the 
crystal structure of doxorubicin and minocycline-bound AcrB (homolog of MexB) 
protein from E. coli. From this study, it shows that the RND components exist as 
asymmetric trimer with individual monomers, in a rotating fashion, adapting one of the 
three conformations that represent the different steps of the drug export process. These 
conformations include access/loose (L) conformation, binding/tight (T) conformation 
and extrusion/open (O) conformation. The efflux process through this rotating 
monomers requires energy from the proton translocation across the membrane 
(Murakami et al., 2006; Seeger et al., 2006). Studies have also shown that, deactivation 
of any one of the three monomers can lead to the dysfunction of the entire trimer 
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(Takatsuka and Nikaido, 2009). Figure 2.4 shows the schematic illustrations of the 
proposed mechanism for RND efflux pump (i.e. AcrB) in the process of drug extrusion. 
 
 
Figure 2.4: Schematic illustrations of substrate and proton pathways in the 
functionally rotation mechanism of AcrB (homolog of MexB). a) Top view of a 
ribbon representation of the AcrB trimer with the antibiotics (in yellow and red colour) 
locates in the binding protomer. The three protomers are colored as green, blue and red, 
according to their conformation: access, binding and extrusion, respectively. b) Top 
view from the distal side of the cell showing rotating motion of the protomers during the 
efflux of drugs. c) The side view of the AcrAB-TolC efflux system parallel to the 
membrane plane. Drugs are illustrated as hexagons. The red lines represent the entrance 
and exit of each protomer. The drug-binding pocket and translocation pathway are 
described as dotted lines. Picture was adapted from (Murakami et al., 2006). 
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Based on Figure 2.4, Murakami et al. (2006) postulated that the individual 
monomer cycles sequentially through these conformational states L, T, O and back to L, 
by three-step functionally rotating mechanism. Initially, the drug first enters the pump in 
the access pocket of the L monomer, and then is the subsequent accommodation of the 
drug in the binding pocket during the L to T transition to the T monomer. Next, the drug 
is extruded in the O monomer into the outer membrane (OM) channel-forming 
constituent through an opening at the top of the RND component as shown in Figure 
2.4(b) and Figure 2.4(c). 
2.5 Strategies to circumvent drug resistance via efflux mechanisms 
 
The dissemination of MDR pathogen in hospital and in the community has 
resulted in challenging treatment of infectious diseases. This problem thus highlights the 
urgency for the development of new compounds that would be able to circumvent the 
drug resistance in bacteria and improve the usefulness/efficacy of both old and new 
generations antibiotics. As described earlier, efflux pumps play a major role in 
contributing to the development of drug resistance, especially in Gram-Negative 
bacteria. Alternatively, the development of efflux pump inhibitor (EPI) appear to be a 
promising strategy to increase the intracellular drug concentration level, restore the 
activity of the drug in the MDR strain, as well as capable to prevent further development 
of resistant strain (Askoura et al., 2011). In addition, the inhibition of the efflux pump 
can be achieved through different mechanisms, such as: 
i. The design of new antibiotics or change the design of the existing antibiotic 
(Chopra, 2002; Vaara, 2010) 
19  
ii. Interfere with the assembly of the efflux pump (for tripartite RND pump) 
(Zgurskaya and Nikaido, 2000; Malléa et al., 2002) 
iii. Block the energy required by the efflux pumps to operate (Mallea et al., 1998) 
 
iv. Competitive or non-competitive inhibition of efflux pumps (Lomovskaya et al., 
2001; Thorarensen et al., 2001) 
v. Interfere with the regulatory steps in the expression of the efflux pump genes 
(Bornet et al., 2003; Yoshihara and Inoko, 2011), and 
vi. Blocking the efflux pump protein/gene (Oethinger and Levy, 2002) 
 
To date, many EPIs have been tested in various drug-resistant bacteria including 
 
E. coli, Enterobacter aerogenes, Klebsiella pneumoniae, Campylobacter jejuni, P. 
aeruginosa and Salmonella enterica serovar Typhimurium (Lomovskaya et al., 2001; 
Thorarensen et al. 2001; Malléa et al., 2002; Chevalier et al., 2004; Bohnert and Kern 
2005). Besides that, several companies such as Microcide, Pfizer, Paratek and several 
academic laboratories have also invested in the search for bacterial EPIs from synthetic, 
natural products and peptidomimetics (Lomovskaya and Bostian, 2006; Bhardwaj and 
Mohanty, 2012). 
An example of established EPI is the carbonyl cyanide m- 
chlorophenylhydrazone (CCCP). This compound which was known as the proton 
uncoupler, could affect the energy required for the efflux pump to operate and the cell 
viability by leading to the dissipation of the proton motive force of the membrane 
(Mahamoud et al., 2007). The efflux pump inhibitory activity of CCCP have been 
reported in Mycobacterium smegmatis (Choudhuri et al., 1999), but to date, CCCP has 
not reached the clinical use due to the high toxicity and adverse effect of this compound 
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on the cell (Mahamoud et al., 2007). Another established EPI, 1-(1-naphthylmethyl)- 
piperazine (NMP) from the members of arylpiperazine family was able to reverse the 
bacterial resistance towards several antibiotics such as chloramphenicol, 
fluoroquinolones and linezolid (Bohnert and Kern, 2005). However, the obscure 
mechanism of action of NMP and its “serotonin agonist” properties have made this 
compound too toxic for clinical usage and unsuitable to act as an EPI (Pagès and 
Amaral, 2009). 
In addition, one of the broad-spectrum and prominent competitive inhibitor of  
the efflux pump being studied in P. aeruginosa is the dipeptide amide, phenylalanine 
arginyl β-napthylamide (PAβN or MC-207, 110). This molecule competitively binds to 
the active site of the efflux pump, thus allowing the entrance of antibiotics into the cell. 
The co-administration of PAβN with levofloxacin has resulted in 8-fold and 32- to 64- 
fold reductions of the levofloxacin MIC in a wild-type strain and efflux pump 
overexpressing strain of P. aeruginosa, respectively (Lomovskaya et al., 2001). 
However, to date, this EPI has not reached the clinical settings probably due to the 
unfavourable pharmacokinetics and toxicological profiles of this compound, and its 
effects on the membrane integrity (Lomovskaya et al., 2001; Lomovskaya and Bostian, 
2006). 
Another group of EPI, pyridopyrimidines, is the other broad-spectrum EPIs that 
have been extensively characterized to date. Its derivative, [{2-[({[(3R)-1-{8-[(4-tert- 
butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(E)-2-(1H-tetrazol-5-yl)ethenyl]-4H- 
pyrido[1,2-a]pyrimidin-2-yl}piperidin-3-yl)oxy}carbonyl)amino]ethyl} 
(dimethyl)ammonio] acetate (ABI-PP) is the AcrAB/MexAB specific EPI. ABI-PP has 
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been identified as a potential EPI candidate due to its high solubility, good safety profile 
in an acute toxicity assay and excellent activity in vivo tested on a rat pneumonia model 
of P. aeruginosa (Yoshida et al., 2007). However, its limitation was that it could only 
inhibit the efflux of all substrates of AcrAB and MexAB efflux systems, but have little 
effect on the other efflux systems (Lomovskaya and Bostian, 2006). Other established 
EPI are the tricyclic neuroleptic phenothiazines such as thioridazine and chlorpromazine. 
The strategy of efflux pump inhibition being hypothesized for these EPIs is such that 
they could disrupt the electron transport chain and the processing of metabolic energy 
that is required by the efflux system (Weinstein et al., 2005; Martins et al., 2011). These 
EPIs have shown their efflux pump inhibitory activity against B. pseudomallei, P. 
aeruginosa, E. coli, S. Typhimurium and S. aureus (Amaral and Lorian, 1991; 
Kristiansen et al., 2003; Chan and Chua, 2005; Spengler et al., 2012). However, the 
direct use of phenothiazines as EPI was not clinically applicable due to the high 
concentration needed to inhibit the bacterial growth in vitro (Zechini and  Versace, 
2009). Figure 2.5 depicts the chemical structure of the aforementioned EPIs. 
To date, many putative EPIs have been discovered, unfortunately, very few of 
them has reached the clinical settings due to the problem of toxicity and their adverse 
clinical outcomes. One EPI candidate that has successful advance to the human clinical 
trial stage is a compound known as MC-601, 205 (Zechini and Versace, 2009). The co- 
administration of an aerosolized formulation of MC-601, 205 with ciprofloxacin has 
reached the phase II clinical trial in the treatment of pulmonary exacerbations of cystic 
fibrosis patient conducted by Mpex Pharmaceuticals. However, to date, the structure and 
specific mode of action of this compound is still unclear (Zechini and Versace, 2009). 
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Figure 2.5: Chemical structure of efflux pump inhibitors 
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Besides that, several other EPIs were only reported on their partial efficacy. This is 
probably due to their limitations on bioavailability, selectivity, stability and toxicity 
(Pagès and Amaral, 2009). Hence, in addressing this matter, the search for natural 
sources or plant-based EPIs offers a potentially safer alternative (Rana et al., 2014; 
Prasch and Bucar, 2015). 
2.6 Efflux pump inhibitor from natural products 
 
For centuries, natural products have already been known as potential source of 
drugs. In general, natural products are naturally occurring substances produced by living 
organisms and also refers to secondary metabolites that are not involved in the main life 
processes (Newman and Cragg, 2012) In fact, plants, which are the main sources of 
natural products, are able to produce many cytotoxic compounds that can protect 
themselves from pathogenic microbes. Thus, this is why less infective diseases are seen 
in wild plants (Stavri et al., 2007). Besides that, the chemical diversity and specific 
action on targets have also made natural products in favor of approaches in drug 
discovery (Prasch and Bucar, 2015). 
The repertoire of phytochemicals in herbs and plants has also contributed to the 
discovery of many plant-based EPIs, recently. One of the ubiquitous phytochemical in 
plants is the caffeic acid derivatives. Caffeic acid is a natural compound that consists of 
both phenolic and acrylic functional groups. It is the major representative of 
hydroxycinnamic acids and the predominant phenolic acids. Caffeic acid is abundant in 
most plants as it is the key intermediate in the biosynthesis of lignin, which is the main 
source of biomass. Besides that, caffeic acid can also be found in our daily foodstuffs 
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and beverages such as asparagus, cabbage, coffee, olives, olive oil, spinach, white 
grapes and wine (Rice-Evans et al., 1996). Figure 2.6 shows the structures of caffeic 
acid and some of its important derivatives. 
 
 
Figure 2.6: Structure of caffeic acid and some of its derivatives 
 
 
Caffeic acid usually exists in plants as various simple derivatives such as 
glycosides, amides, esters and sugar esters (Cowan, 1999; Touaibia and Doiron, 2011). 
Some of the important caffeic acid derivatives include chlorogenic acid (3-O- 
caffeoylquinic acid) and caffeic acid phenethyl ester (CAPE). Chlorogenic acids are 
formed from the esterification of hydroxycinnamic acids (e.g. caffeic acid, ferulic, p- 
coumaric acid) and quinic acid. Chlorogenic acid is one of the main components in 
